Tamoxifen-associated steatohepatitis--report of three cases
- PMID: 8530816
- DOI: 10.1016/0168-8278(95)80316-5
Tamoxifen-associated steatohepatitis--report of three cases
Abstract
The authors describe three cases of tamoxifen-associated steatohepatitis, which resulted from a daily dosage of 20 mg used as the adjuvant treatment of breast carcinoma. Liver tests became normal after discontinuation of tamoxifen.
Similar articles
-
Tamoxifen-induced steatohepatitis.Ann Intern Med. 1995 Aug 1;123(3):236. doi: 10.7326/0003-4819-123-3-199508010-00018. Ann Intern Med. 1995. PMID: 7598311 No abstract available.
-
[Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].Gastroenterol Clin Biol. 2000 Nov;24(11):1122-3. Gastroenterol Clin Biol. 2000. PMID: 11139682 French.
-
Tamoxifen-induced hepatotoxicity.Indian J Cancer. 2011 Jul-Sep;48(3):385. doi: 10.4103/0019-509X.84935. Indian J Cancer. 2011. PMID: 21921356 No abstract available.
-
[Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma].Bull Cancer. 1992;79(10):969-77. Bull Cancer. 1992. PMID: 1292764 Review. French.
-
[Toxic hepatitis associated with tamoxifen use. A case report and literature review].Gastroenterol Hepatol. 2002 Apr;25(4):247-50. doi: 10.1016/s0210-5705(02)70254-9. Gastroenterol Hepatol. 2002. PMID: 11975873 Review. Spanish.
Cited by
-
Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of "pseudocirrhosis".Dig Dis Sci. 2007 Mar;52(3):749-52. doi: 10.1007/s10620-006-9332-9. Dig Dis Sci. 2007. PMID: 17265127 No abstract available.
-
Fatty metamorphosis of the liver in patients with breast cancer: possible associated factors.World J Gastroenterol. 2003 Jul;9(7):1618-20. doi: 10.3748/wjg.v9.i7.1618. World J Gastroenterol. 2003. PMID: 12854178 Free PMC article.
-
NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment.Endocrinology. 2020 Oct 1;161(10):bqaa134. doi: 10.1210/endocr/bqaa134. Endocrinology. 2020. PMID: 32776116 Free PMC article. Review.
-
Dose adaptation of antineoplastic drugs in patients with liver disease.Drug Saf. 2006;29(6):509-22. doi: 10.2165/00002018-200629060-00004. Drug Saf. 2006. PMID: 16752933 Review.
-
Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice.J Clin Invest. 2000 Jun;105(12):1819-25. doi: 10.1172/JCI9575. J Clin Invest. 2000. PMID: 10862797 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical